Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ozuriftamab vedotin - BioAtla

Next Previous
Drug Profile

Ozuriftamab vedotin - BioAtla

Alternative Names: BA-3021; BA302; CAB-ROR2-ADC; HTBA-3021; Oz-V - BioAtla

Latest Information Update: 11 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioAtla
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Cell death stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Squamous cell cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 02 Jun 2025 Updated efficacy and safety data from a phase II trial in Squamous cell cancer released by BioAtla
  • 27 Mar 2025 Updated adverse events and efficacy data from a phase-II trial in Squamous cell cancer released by BioAtla
  • 30 Dec 2024 BioAtla completes a phase I/II trial in Malignant melanoma (Combination therapy, Second-line therapy or greater) in the US, Hongkong, Germany, Greece, Poland, Italy, Spain and Taiwan. (Parenteral) (NCT03504488) (EudraCT2022-000137-17)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top